Indivior Pharmaceuticals, Inc. (INDV)
NASDAQ: INDV · Real-Time Price · USD
41.83
+0.54 (1.31%)
At close: Jun 26, 2026, 4:00 PM EDT
41.96
+0.13 (0.31%)
After-hours: Jun 26, 2026, 7:59 PM EDT
Indivior Pharmaceuticals Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Indivior Pharmaceuticals stock have an average target of 50.75, with a low estimate of 46 and a high estimate of 59. The average target predicts an increase of 21.32% from the current stock price of 41.83.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Indivior Pharmaceuticals stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 2 | 2 | 2 | 1 | 1 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 6 | 6 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy Initiates $46 | Buy | Initiates | $46 | +9.97% | Jun 18, 2026 |
| Craig-Hallum | Craig-Hallum | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Jun 4, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $54 → $59 | Buy | Reiterates | $54 → $59 | +41.05% | May 22, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $48 | Buy | Reiterates | $48 | +14.75% | Apr 30, 2026 |
| Northland Securities | Northland Securities | Buy Maintains $50 | Buy | Maintains | $50 | +19.53% | Feb 27, 2026 |
Financial Forecast
Revenue This Year
1.26B
from 1.24B
Increased by 1.53%
Revenue Next Year
1.29B
from 1.26B
Increased by 2.34%
EPS This Year
3.82
from 2.50
Increased by 52.99%
EPS Next Year
3.97
from 3.82
Increased by 3.76%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 1.3B | 1.3B | |
| Avg | 1.3B | 1.3B | |
| Low | 1.2B | 1.2B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 3.4% | 6.4% | |
| Avg | 1.5% | 2.3% | |
| Low | -0.3% | -5.8% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 4.05 | 4.27 | |
| Avg | 3.82 | 3.97 | |
| Low | 3.63 | 3.10 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 62.0% | 11.6% | |
| Avg | 53.0% | 3.8% | |
| Low | 45.2% | -19.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.